purpos
review
sever
acut
respiratori
syndrom
coronaviru
viru
respons
aggress
coronaviru
diseas
pandem
recent
investig
stipul
patient
receiv
angiotensinconvertingenzym
inhibitor
acei
may
subject
poorer
outcom
editori
present
avail
evid
guid
treatment
practic
pandem
recent
find
recent
studi
wuhan
cohort
provid
valuabl
inform
cohort
critic
ill
patient
reveal
cardiac
injuri
patient
wors
outcom
appear
preval
patient
hypertens
diabet
mellitu
dm
possibl
due
overexpress
angiotensinconvert
enzym
receptor
airway
alveolar
epitheli
cell
investig
suspect
use
receptor
enter
lung
mechan
similar
sarscov
sever
hypothes
propos
date
regard
net
effect
aceiarb
infect
posit
effect
includ
receptor
blockad
disabl
viral
entri
heart
lung
overal
decreas
inflamm
secondari
aceiarb
neg
effect
includ
possibl
retrograd
feedback
mechan
receptor
upregul
summari
even
though
physiolog
model
sarscov
infect
show
theoret
benefit
aceiarb
find
extrapol
caus
major
cardiolog
scientif
associ
includ
acc
hfsa
aha
esc
hypertens
council
reject
correl
hypothes
extens
literatur
review
conclud
signific
evid
support
associ
given
rapid
evolv
pandem
find
may
chang
sever
acut
respiratori
syndrom
coronaviru
viru
respons
global
pandem
catastroph
consequ
healthcar
system
popul
around
world
initi
describ
decemb
wuhan
china
viru
rapidli
escal
march
world
health
organ
declar
pandem
share
similar
sarscov
viru
respons
sar
epidem
middl
eastern
respiratori
syndrom
coronaviru
mer
viru
respons
mer
follow
sar
epidem
research
extens
investig
pathophysiolog
mechan
sarscov
infect
includ
interact
viru
heart
lung
base
studi
research
believ
angiotensinconvert
enzym
receptor
locat
alveolar
epitheli
cell
serv
high
affin
receptor
cotransport
enter
lung
medic
angiotensinconvert
enzym
inhibitor
acei
block
receptor
may
predispos
protect
infect
editori
summar
current
scientif
evid
surround
subject
order
guid
clinic
practic
juan
simon
ricomesa
averi
white
share
first
authorship
reninangiotensinaldosteron
system
raa
maintain
plasma
sodium
concentr
via
feedback
blood
pressur
baroreceptor
sodium
potassium
level
first
kidney
secret
renin
metabol
angiotensinogen
angiotensin
next
kidney
lung
secret
ace
convert
angiotensin
angiotensin
ii
final
angiotensin
ii
stimul
vasoconstrict
cardiovascular
respons
aldosteron
adh
product
ultim
increas
blood
pressur
bodi
fluid
volum
sodium
potassium
free
water
resorpt
receptor
homolog
angiotensin
iconvert
enzym
ace
receptor
type
transmembran
aminopeptidas
high
express
heart
lung
tissu
also
express
endothelium
kidney
see
fig
illustr
raa
activ
pathway
discov
receptor
appear
counterregul
raa
activ
degrad
angiotensin
ii
raa
system
wide
implic
dm
hypertens
heart
failur
acei
arb
drug
base
upon
strong
evid
efficaci
commonli
use
manag
hypertens
heart
failur
post
myocardi
infarct
care
slow
progress
renal
diseas
associ
diabet
exponenti
rise
case
worldwid
observ
studi
identifi
risk
factor
infect
poor
outcom
three
separ
studi
identifi
hypertens
dm
highli
preval
among
patient
accord
yang
et
al
among
critic
ill
patient
dm
present
case
b
accord
guan
et
al
among
patient
dm
present
case
hypertens
present
case
c
accord
zhang
et
al
among
hospit
patient
dm
present
case
hypertens
present
case
hypertens
dm
treat
acei
arb
medic
use
assess
three
aforement
studi
lead
inconclus
hypothesi
howev
one
studi
date
analyz
effect
acei
arb
use
popul
accord
peng
et
al
among
patient
cardiovascular
comorbid
led
wors
outcom
death
occur
secondari
fulmin
inflamm
lactic
acidosi
thrombot
state
acei
arb
use
influenc
morbid
mortal
addit
observ
wellknown
associ
virus
sarscov
merscov
deleteri
cardiac
event
includ
cardiac
injuri
sarscov
well
myocard
heart
failur
merscov
furthermor
recent
associ
cardiac
injuri
defin
troponin
pgml
electrocardiogramechocardiogram
abnorm
patient
cohort
data
demonstr
cardiac
affin
three
virus
etiolog
cardiac
damag
patient
unclear
receptor
may
play
role
given
high
affin
sarscov
receptor
recent
fig
raa
pathway
show
aceiarb
mechan
action
sar
infecti
mechan
via
receptor
commentari
publish
lancet
respiratori
medicin
hypothes
use
receptor
increas
drug
higher
risk
sever
infect
acei
initi
inhibit
ace
lead
decreas
angiotensin
level
caus
possibl
neg
feedback
loop
ultim
upregul
receptor
abl
interact
decreas
angiotensin
substrat
avail
see
fig
receptor
upregul
result
increas
bind
site
lead
preferenti
infect
particularli
observ
patient
diabet
andor
hypertens
sinc
usual
take
acei
arb
comment
releas
find
publish
peng
et
al
editori
respons
sommerstein
et
al
base
find
ferrario
et
al
show
increas
level
lisinopril
increas
level
losartan
publish
british
medic
journal
convers
investig
argu
acei
arb
use
may
benefici
infect
prevent
li
et
al
exampl
propos
acei
inhibit
ace
may
stimul
neg
feedback
given
lack
angiotensin
ii
upregul
receptor
decreas
overal
inflamm
sun
et
al
argu
acei
use
im
pair
aceangiotensin
receptor
pathway
therefor
impair
integr
ma
masrel
g
proteincoupl
receptor
disrupt
pathway
could
lead
decreas
product
decreas
chanc
enter
cell
raa
inactiv
anim
model
demonstr
symptom
relief
acut
sever
pneumonia
respiratori
failur
vasoconstrict
mechan
recent
find
also
demonstr
patient
arb
olmesartan
increas
secret
urinari
like
upregul
mechan
although
unclear
despit
hypothesi
upregul
causal
relationship
decreas
mortal
demonstr
final
given
contradictori
hypothes
rapidli
evolv
natur
diseas
social
mediarel
hysteria
sever
cardiolog
associ
hfsaaccaha
esc
hypertens
council
releas
offici
statement
regard
continu
acei
arb
patient
associ
strongli
recommend
continu
treatment
aceiarb
patient
previous
take
either
class
medic
lack
scientif
evid
clinic
data
support
discontinu
acearb
use
patient
coexist
heart
failur
hypertens
ischem
heart
diseas
wellstudi
reduct
mortal
confer
acearb
use
benefici
effect
patient
diabet
chronic
kidney
diseas
proteinuria
albuminuria
current
outweigh
theoret
risk
pandem
continu
rapidli
evolv
affect
patient
cardiovascular
comorbid
research
need
clarifi
accuraci
exist
hypothes
conflict
interest
dr
ricomesa
ms
white
noth
disclos
dr
anderson
receiv
honoraria
novarti
pfizer
consult
edward
lifesci
receiv
research
support
abbott
human
anim
right
inform
consent
manuscript
contain
studi
human
anim
subject
